Technology

The capabilities developed within ProCan Technologies present an opportunity to incorporate proteomics into clinical trials. We anticipate that proteomic signatures indicative of patient responsiveness to the drug being trialed, will be able to be detected in the early phase clinical trials. Following successful identification of signatures that can stratify patients, these signatures can subsequently be developed as patient selection tools for the later, larger trials and as a companion diagnostic when the drug reaches the market.

• Detects 2 to 5 times more proteins compared to biofluid analysis.
• Utilises Mass Spectrometry (MS) technologies to capture over 80% of the entire human proteome.
• Enables direct comparison with histopathological features, including cancer content and tumour lymphocyte infiltration.
• Provides insights into the tumour microenvironment and tissue of origin.
• Detects elevated levels of potential biomarkers with greater accuracy.
• Integrates seamlessly with the patient’s clinical and diagnostic pathway.

Direct Protein Measurement:

• Enables precise measurement of protein abundance.

Superior Comparability

• Our DIA Mass Spectrometry technology allows for consistent comparisons across different time points and machines.
• Unlike other technologies, there’s usually no need to re-run cohorts for comparisons across different time points—a critical advantage for longitudinal studies.

Novel Biomarker and Therapeutic Target Discovery:

• Facilitates the identification of new biomarkers and potential therapeutic targets.

Building Blocks of Proteins:

• Mass spectrometric proteomic technology directly identifies peptides unique to a specific protein, offering greater accuracy than antibody-based methods.

Enhanced Confidence in Protein Detection:

• Multiple peptide identifications per protein increase the reliability of protein identification and quantification.

Untargeted Protein Discovery:

• DIA Mass Spectrometry is untargeted, capable of discovering a vast array of proteins.

Comprehensive Protein Detection:

• DIA Mass Spectrometry protein identifications are not restricted to a predefined subset of the proteome.
• This capability allows for the discovery of novel proteins or biomarkers that other approaches might miss.

Retrospective Analysis:

• Enables analysis of banked samples (e.g., Formalin-Fixed Paraffin-Embedded /Fresh Frozen tissue samples), offering the ability to revisit and investigate archived samples.

Targeted Analysis When Needed:

• Targeted assays for absolute quantification of specific proteins using mass spectrometry, e.g. using Selected Reaction Monitoring (SRM), can be developed to focus on particular proteins of interest.

For Tissue Samples:

• We can analyse Formalin-Fixed, Paraffin-Embedded or Fresh Frozen samples.
• Samples can be sectioned by the client or our team (sectioning by us is an additional service).
• Compatible with any tissue type, not limited to cancer tissues.
• Requires 10-30µm sections.
• Preferred sample submission in a low-binding 0.6ml push-top tube (non-screwcap) which we can supply.

For Biofluid Samples:

• Coming soon – please enquire.